Online first
Guidelines / Expert consensus
Published online: 2024-11-28

open access

Page views 50
Article views/downloads 20
Get Citation

Connect on Social Media

Connect on Social Media

Nivolumab with relatlimab in the treatment of melanoma patients — the position of the Section of Immuno-oncology of the Polish Society of Oncology

Bożena Cybulska-Stopa12, Jacek Mackiewicz34, Hanna Koseła-Paterczyk5, Grażyna Kamińska-Winciorek67, Adam Maciejczyk28, Anna M. Czarnecka59, Sebastian Giebel7, Monika Durzyńska10, Manuela Las-Jankowska1112, Magdalena Suchorzepka-Simek613, Piotr Rutkowski5

Abstract

Treatment of melanoma patients has undergone significant modification in recent years, resulting in improved outcomes. Still, the prognosis of patients with advanced stage or metastatic disease is not the best, and new therapeutic options are being sought. One direction of research is the combination of molecules with different mechanisms of action, the so-called fixed-dose combination (FDC) formulations, which are expected to improve the quality of life and safety of patients and provide improved treatment outcomes. This article presents the position of the Immunooncology Section of the Polish Society of Oncology on the use of the combination of nivolumab and relatlimab in the treatment of patients with inoperable melanoma or metastatic disease.

Article available in PDF format

View PDF Download PDF file

References

  1. Thangaraju P, Varthya SB, Venkatesan S. Fixed-dose combinations: An essential for rational preparation. Indian J Pharmacol. 2021; 53(2): 170–172.
  2. Phillips AL, Reeves DJ. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma. Ann Pharmacother. 2023; 57(6): 738–745.
  3. https://www.drugs.com/history/opdualag.html (21.09.2024).
  4. https://ec.europa.eu/health/documents/community-register/2022/20220915156787/anx 156787_pl.pdf (21.09.2024).
  5. Koseła-Paterczyk H, Rutkowski P. Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma. Expert Opin Biol Ther. 2023; 23(5): 383–388.
  6. Tawbi HA, Schadendorf D, Lipson EJ, et al. RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1): 24–34.
  7. Ascierto PA, Lipson EJ, Dummer R, et al. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. J Clin Oncol. 2023; 41(15): 2724–2735.
  8. Wolchok J, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022; 40(2): 127–137.
  9. Hodi F, -Sileni VC, Lewis K, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. J Clin Oncol. 2022; 40(16_suppl): 9522–9522.
  10. Long GV, Lipson EJ, Hodi FS, et al. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. J Clin Oncol. 2024 [Epub ahead of print]: JCO2401125.
  11. Zhao BW, Zhang FY, Wang Y, et al. LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials. Cancers (Basel). 2022; 14(20).
  12. Boutros A, Tanda ET, Croce E, et al. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. Eur J Cancer. 2023; 188: 64–79.
  13. Thakker S, Belzberg M, Jang S, et al. Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatlimab. Oncologist. 2024 [Epub ahead of print].
  14. Jang S, Stahl C, Al-Mondhiry J, et al. Efficacy of nivolumab and relatlimab-rmbw in patients with advanced melanoma who were previously treated with PD-1 inhibitor: Real world experience. J Clin Oncol. 2023; 41(16_suppl): e21533–e21533.